Log in
NASDAQ:IPHA

Innate Pharma Stock Forecast, Price & News

$3.86
+0.10 (+2.66 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.65
Now: $3.87
$3.87
50-Day Range
$3.77
MA: $5.53
$6.55
52-Week Range
$3.30
Now: $3.87
$8.24
Volume6,452 shs
Average Volume19,141 shs
Market Capitalization$295.84 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for cutaneous T-cell lymphomas; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications and tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. It also provides IPH5201, an anti-CD39 antibody and IPH5301, an anti-CD73 antibody, which is in pre-clinical stage for the treatment of immuno-oncology. In addition, the company offers IPH61, a bispecific NK cell engager that is used to create novel molecular formats to kill tumor cells through NKp46. Further, it provides Lumoxiti, a commercial-stage oncology product for treating hairy cell leukemia. Innate Pharma S.A. has licensing agreements with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi; and a clinical trial collaboration with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.17 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IPHA
CUSIPN/A
CIKN/A
Phone33-4-30-30-30-30

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$96.12 million
Book Value$3.18 per share

Profitability

Miscellaneous

Employees200
Market Cap$295.84 million
Next Earnings DateN/A
OptionableNot Optionable
$3.86
+0.10 (+2.66 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IPHA News and Ratings via Email

Sign-up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Innate Pharma (NASDAQ:IPHA) Frequently Asked Questions

How has Innate Pharma's stock price been impacted by COVID-19 (Coronavirus)?

Innate Pharma's stock was trading at $6.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IPHA shares have decreased by 38.7% and is now trading at $3.8650.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Innate Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Innate Pharma
.

What price target have analysts set for IPHA?

3 analysts have issued 1 year price objectives for Innate Pharma's shares. Their forecasts range from $7.00 to $7.00. On average, they expect Innate Pharma's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 81.1% from the stock's current price.
View analysts' price targets for Innate Pharma
.

Are investors shorting Innate Pharma?

Innate Pharma saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 29,300 shares, an increase of 70.3% from the August 31st total of 17,200 shares. Based on an average trading volume of 10,000 shares, the short-interest ratio is presently 2.9 days.
View Innate Pharma's Short Interest
.

Who are some of Innate Pharma's key competitors?

What other stocks do shareholders of Innate Pharma own?

Who are Innate Pharma's key executives?

Innate Pharma's management team includes the following people:
  • Dr. Hervé Brailly, Co-Founder & Chairman of Supervisory Board (Age 58)
  • Dr. Mondher Mahjoubi, Chairman of Exec. Board & CEO (Age 61)
  • Mr. Yannis Morel, Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board (Age 46)
  • Ms. Laure-Hélène Mercier M.B.A., M.Sc., MSc, MBA, Exec. VP, CFO & Member of Exec. Board (Age 41)
  • Mr. Eric Vivier D.V.M., Ph.D., Sr. VP & Chief Scientific Officer (Age 55)

When did Innate Pharma IPO?

(IPHA) raised $80 million in an initial public offering (IPO) on Thursday, October 17th 2019. The company issued 10,700,000 shares at a price of $7.50 per share. Citigroup, SVB Leerink and Evercore ISI served as the underwriters for the IPO.

What is Innate Pharma's stock symbol?

Innate Pharma trades on the NASDAQ under the ticker symbol "IPHA."

How do I buy shares of Innate Pharma?

Shares of IPHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innate Pharma's stock price today?

One share of IPHA stock can currently be purchased for approximately $3.87.

How big of a company is Innate Pharma?

Innate Pharma has a market capitalization of $295.84 million and generates $96.12 million in revenue each year. The company earns $-23,250,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Innate Pharma employs 200 workers across the globe.

What is Innate Pharma's official website?

The official website for Innate Pharma is www.innate-pharma.com.

How can I contact Innate Pharma?

Innate Pharma's mailing address is 117 AVENUE DE LUMINY BP 30191, MARSEILLE I0, 13009. The company can be reached via phone at 33-4-30-30-30-30 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.